NCT06531915View on ClinicalTrials.gov

Comparison of Efficacy and Safety Between Ciprofol and Remimazolam During Fiberoptic Bronchoscopy

NANot yet recruitingINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

March 31, 2025

Conditions

Fiberoptic Bronchoscopy

Interventions

DRUG

Ciprofol

Participants in the ciprofol group will be intravenously injected with 0.4 mg/kg of ciprofol (batch number H20200013, Haisike Pharmaceutical Co., Ltd., Liaoning, China) and sufentanil (0.2 μg/kg).

DRUG

Remimazolam

Participants in the remimazolam group will be intravenously injected with 0.1 mg/kg of remimazolam besylate (batch number HR7056, Hengrui Pharmaceutical Co., Ltd., Jiangsu, China) and sufentanil (0.2 μg/kg).

All Listed Sponsors

lead

Anhui Provincial Hospital

OTHER_GOV

NCT06531915 - Comparison of Efficacy and Safety Between Ciprofol and Remimazolam During Fiberoptic Bronchoscopy | Biotech Hunter | Biotech Hunter